Dr. Reddy's Laboratories (RDY) DIvidends Date & History

Key Takeaways

• Dr. Reddy's Laboratories (RDY) offers a current dividend yield of approximately 0.54%, with an annual payout of $0.071 per share.
• The company pays dividends annually, with the most recent ex-dividend date on July 25, 2025, and payment on August 6, 2025.
• Extremely low payout ratio of 9.46% ensures high sustainability, backed by strong earnings coverage.
• Free cash flow generation supports the dividend comfortably, aided by a net cash position and low debt levels.
• Recent 1-year dividend growth was -11.54%, but 5-year trends show periods of increase amid overall stability.
• Attractive for conservative investors prioritizing safety over high yield in the generics pharmaceutical sector.

Dividend Overview

Dr. Reddy's Laboratories (RDY), a leading global generics pharmaceutical company, maintains a modest dividend policy focused on sustainability rather than aggressive payouts. The current annual dividend stands at $0.071 per share, delivering a yield of about 0.54% based on recent trading levels. Payments are made annually, typically in August following an ex-dividend date in late July. This profile positions RDY as neither a high-yield stock nor a rapid dividend growth contender, but rather a reliable payer with a conservative approach. The low yield reflects the company's strategy to reinvest heavily in R&D (research and development) and manufacturing capacity for complex generics, prioritizing long-term growth in a competitive industry. Earnings comfortably cover the dividend, underscoring its stability for income-oriented portfolios.

Dividend History and Growth

Dr. Reddy's Laboratories has paid dividends consistently for over two decades, with annual distributions reflecting India's regulatory norms for listed companies. Recent history shows stability with modest fluctuations: $0.08083 in 2024 (ex-date July 30), $0.08198 in 2023 (ex-date July 28), $0.06342 in 2022 (ex-date August 1), and $0.05595 in 2021 (ex-date July 8). The 2025 payout of $0.0715 (ex-date July 25) represents a 1-year decline of 11.54%, influenced by a 1:5 stock split in late 2024 and currency adjustments. Over five years, growth has averaged around 9-10% in some metrics, though not a streak of consecutive increases. The company avoids cuts, maintaining payments through economic cycles, with a long-term strategy tied to profitability in generics and biosimilars.

Dividend Sustainability and Payout Ratio

The dividend's sustainability is robust, highlighted by a trailing twelve-month (TTM) payout ratio of just 9.46%, meaning only a fraction of earnings is distributed, leaving ample room for reinvestment or growth. Earnings per share (EPS) of approximately $0.71-0.74 easily cover the $0.071 payout. Free cash flow (FCF), while varying quarterly due to capex (capital expenditures) in sterile injectables, generated positive annual figures like $0.361 billion in recent years, exceeding dividend needs. Balance sheet strength bolsters this: negative net debt (cash exceeds borrowings), a debt-to-equity ratio around 0.12-0.21, and high interest coverage over 60x. Operating margins near 22% and ROIC (return on invested capital) above 30% signal financial health, positioning the dividend as highly secure absent major disruptions.

Dividend Compared to Industry Peers

In the generics pharmaceutical sector, Dr. Reddy's Laboratories' 0.54% yield is low to modest compared to peers. VTRS (Viatris), a direct competitor in generics, offers a higher 2.8% yield with quarterly payments of $0.12 ($0.48 annualized), though from a higher payout base amid past M&A (mergers and acquisitions) integration. TEVA (Teva) pays no dividend currently, focusing on debt reduction post-challenges. Indian peers like Sun Pharma (ADR equivalent yield ~0.9%) and Lupin (~0.5%) align closely with RDY's conservative stance, emphasizing growth over yield. Overall, RDY's profile suits investors valuing safety over income volume in a sector averaging 1-3% yields.

AI Screener

Tickeron’s AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. It excels at identifying dividend stocks, income-focused investments, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. Explore the AI Screener to uncover hidden gems like sustainable dividend payers in pharmaceuticals.

Is This Stock Attractive for Dividend Investors?

Dr. Reddy's Laboratories (RDY) appeals to conservative, long-term dividend investors who prioritize safety and capital preservation over high current income. Its ultra-low payout ratio and net cash balance sheet provide a wide margin of safety, ideal for those wary of yield traps in volatile pharma sectors. Growth-oriented dividend investors may appreciate the historical 8-10% average increases in select periods, fueled by generics pipeline and U.S. market share gains, though recent dips temper expectations for rapid compounding. Income seekers needing 3-5% yields might look elsewhere, like higher-payers such as VTRS, but RDY's stability suits retirees or institutions favoring low-risk exposure to emerging market pharma leaders. Balanced against moderate growth prospects and R&D reinvestment, it fits portfolios emphasizing resilience amid patent cliffs and pricing pressures, without chasing unsustainable yields.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations